Young children with mixed lineage leukaemia rearranged infant acute lymphoblastic leukaemia (MLLriALL) still have a very poor prognosis. While CAR T-cell therapy – a new type of treatment that uses the body’s own defences against cancer – is very effective against certain types of leukaemia, it has been challenging to treat MLLriALL this way. Dr Anindita Roy and her team aim to overcome these challenges by developing a modified form of CAR T-cell therapy that is effective against MLLriALL. They hope it will be ready for clinical trials when the project ends in three years, so that it can start improving outcomes for patients.
Improving immunotherapies for the treatment of leukaemia
Dr Anindita Roy and Professor Anastasios Karadimitris
University of Oxford and Imperial College London
Oxford, OX1 2JD; London, SW7 2BU